SIMULTANEOUS INTEGRATED BOOST USING CONFORMAL RADIATION THERAPY FOR TREATMENT OF CERVICAL CANCER

Purpose: Chemoradiation is the treatment of choice for locally advanced cervical cancer. At our institution, we have been using forward planned conformal radiation therapy to treat patients to the whole pelvis with asimultaneous integrated boost (SIB) to the uterus and parametria. Our aim is to report the local control, disease free survival, overall survival, and toxicities of definitive chemoradiation with SIB for treatment of cervical cancer. Methods: Medical records and treatment plans of patients with cervical cancer treated from 2009-2013 were reviewed using an IRB-approved database. The records of patients with cervical cancer treated with definitive chemoradiation and a three dimensional forward planned SIB were analyzed to determine local failure, distant failure, overall survival, and rate of toxicities. Results: Twenty one patients were treated with definitive chemoradiation with a SIB. Median follow up time was 18.1 months. The 2-year LC rate was 95.2%, the 2-year DFS was 80.9%, and there were no deaths, for an overall survival rate of 100%. One patient experienced Grade 3 or higher acute toxicity, and two patients experienced Grade 3 or higher late toxicities. Conclusions: This study demonstrates the feasibility and tolerability of SIB using forward planned conformal radiation therapy for the treatment of cervical cancer. This radiation technique can be used to deliver a higher dose to the area most at risk for recurrence in a shorter treatment time